Meissa Vaccines (United States)
- Research works
- 3 ▲ 1543% vs 2013–17
- Citations
- 38 13.2 per fractional work
- Top-10% rate
- 80.6% record average 16.5%
- Open access
- 92% world 28%
Not ranked overall: Meissa Vaccines (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Which research topics does Meissa Vaccines (United States) publish most on?
By volume in 2022–2025: COVID-19 Clinical Research Studies, Dermatological and COVID-19 studies, Respiratory viral infections research and Long-Term Effects of COVID-19.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 COVID-19 Clinical Research Studies Infectious Diseases 0 works
- 2 Dermatological and COVID-19 studies Dermatology 0 works
- 3 Respiratory viral infections research Epidemiology 0 works
- 4 Long-Term Effects of COVID-19 Neurology 0 works
- 5 Viral gastroenteritis research and epidemiology Infectious Diseases 0 works
- 6 SARS-CoV-2 and COVID-19 Research Infectious Diseases 0 works
- 7 vaccines and immunoinformatics approaches Molecular Biology 0 works
- 8 Virology and Viral Diseases Epidemiology 0 works
- 9 Bacteriophages and microbial interactions Ecology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Meissa Vaccines (United States)'s research output changed?
Output in 2018–2022 was 1543% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in South San Francisco
- Sunesis (United States)
- Exelixis (United States)
- Kaiser Permanente South San Francisco Medical Center
- Cytokinetics (United States)
- Portola Pharmaceuticals (United States)
- NGM Biopharmaceuticals (United States)
- Rapt Therapeutics (United States)
- Atara Biotherapeutics (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.